| 16189265 |
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
Fabbro, D,
Valent, P,
Sonneck, K,
Gleixner, KV,
Böhm, A,
Samorapoompichit, P,
Aichberger, KJ,
Gruze, A,
Sillaber, C,
Mayerhofer, M,
Pickl, WF,
Manley, PW,
Derdak, S
|
Blood |
2006 |
| 15972446 |
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Kajiguchi, T,
Durocher, JA,
Gilliland, DG,
Chen, CC,
Heinrich, MC,
Ruan, J,
Lichy, JH,
Coutré, SE,
Galli, SJ,
Wang, Y,
Lilleberg, SL,
George, TI,
Williams, C,
Arber, DA,
Growney, JD,
Neckers, L,
Berubé, C,
Gotlib, J,
Cohen, PS
|
Blood |
2005 |
| 15790786 |
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412
Griffin, JD,
Gilliland, DG,
Adelsperger, J,
Fabbro, D,
Clark, JJ,
Stone, R,
Growney, JD
|
Blood |
2005 |
